Does Semaglutide Cause Hair Loss? (Ozempic & Wegovy Explained)

Does Semaglutide Cause Hair Loss? The Direct Answer

Yes. Semaglutide, the active ingredient in Ozempic, Wegovy, and Rybelsus, can trigger hair shedding in a subset of users. The cause is almost always telogen effluvium, a temporary condition where a large cohort of hair follicles enters the resting phase at the same time and sheds about three months later. This is not a direct toxic effect of the semaglutide molecule on hair follicles. It is a downstream consequence of rapid weight loss and caloric restriction, both of which semaglutide produces effectively.

What distinguishes semaglutide from tirzepatide here is the label. Alopecia is listed in the Wegovy prescribing information as a labeled adverse event; the Zepbound and Mounjaro labels do not list it. For semaglutide at the 2.4 mg weight-management dose, the trial signal was recognized in the label.

The Mechanism: Telogen Effluvium, Not Drug Toxicity

Each hair follicle cycles independently through three phases: anagen (active growth, 2 to 7 years), catagen (transition, about 2 weeks), and telogen (resting and shedding, about 3 months). Normally, 85 to 90 percent of follicles sit in anagen at any given time, keeping shedding manageable at 50 to 100 strands per day.

A significant physiological stressor pushes a large cohort of follicles out of anagen at once. Three months later they shed simultaneously, producing the diffuse thinning that defines telogen effluvium. Surgery, illness, childbirth, and rapid weight loss are all known triggers. The 2025 peer-reviewed review by Haykal and colleagues, published as PMC11909624, concluded that "preliminary evidence strongly suggests an association between semaglutide therapy and alopecia," with telogen effluvium as the working mechanism. The drug does not poison follicles. The weight change stresses them.

What Makes Semaglutide a Potent Telogen Effluvium Trigger

In the STEP 1 trial (Wilding et al., NEJM 2021; PMID 33567185), the semaglutide 2.4 mg arm lost 14.9 percent of body weight at 68 weeks. That magnitude and pace of weight change is precisely what produces a population-scale telogen effluvium signal. Hair shafts are roughly 95 percent keratin, so when protein allocation gets cut by sharp caloric restriction, hair production gets cut first. Onset is typically 2 to 4 months after rapid weight loss begins, consistent with the lag between telogen entry and the shedding event; many users notice nothing during early titration, then see a marked uptick around month 3 or 4.

What Does the Evidence Show? Semaglutide Hair Loss Data

The Wegovy FDA Label: Alopecia IS Listed

This is the key differentiator between semaglutide and tirzepatide hair loss. The Wegovy prescribing information lists alopecia in its adverse events table at low frequency for the 2.4 mg weight-management dose; the Zepbound and Mounjaro tirzepatide labels do not list it. Exact incidence varies by label revision, so we report it conservatively: alopecia appears in the Wegovy label at low frequency, above placebo.

2026 Population Cohort and Review Findings

Three 2026-era studies build the case:

• Haykal et al. (PMC11909624), 2025: A semaglutide-specific review concluded "preliminary evidence strongly suggests an association between semaglutide therapy and alopecia." This is the top-ranked organic result for the query and is the only semaglutide-only review in the published literature. It frames the mechanism as telogen effluvium and discusses patient counseling.
• Herrera and Bordeaux, Journal of the American Academy of Dermatology (PMID 41707704), 2026: A retrospective TriNetX cohort analysis confirmed an association between semaglutide and tirzepatide use and new-onset hair loss at the population scale. Publication in JAAD gives the finding strong clinical weight.
• Gupta et al., Science Progress (PMID 41998799), 2026: A systematic review of GLP-1 therapies and hair loss found that semaglutide and tirzepatide "demonstrated the highest incidence rates of hair loss and more frequent signal detection in pharmacovigilance studies" among the GLP-1 class. The review identified females as disproportionately affected and noted a dose-dependent pattern.

How Semaglutide Hair Loss Compares to Tirzepatide

Semaglutide and tirzepatide are both in the highest-incidence tier of the GLP-1 class for hair loss according to Gupta et al. 2026. The label status differs: Wegovy lists alopecia, Zepbound and Mounjaro do not. The trial weight loss differs as well: semaglutide 2.4 mg produced 14.9 percent in STEP 1; tirzepatide 15 mg produced 20.9 percent in SURMOUNT-1. Greater absolute weight change is a stronger telogen effluvium trigger, but semaglutide's longer titration schedule (0.25 mg through 2.4 mg across five dose levels) keeps people at higher cumulative dose exposure during the early shedding window. For the full side-by-side, see the companion tirzepatide hair loss article and the tirzepatide vs semaglutide comparison.

Who Is Most at Risk of Hair Loss on Semaglutide?

Not everyone who loses weight on semaglutide notices meaningful shedding. Several factors raise risk, and recognizing them early lets you act on the modifiable ones before shedding begins.

• Higher dose (especially 2.4 mg Wegovy): The faster and deeper the weight loss, the more follicles enter telogen together. The 2.4 mg weight-management dose carries the highest signal.
• Faster rate of weight loss: Independent of absolute dose, people who lose weight quickly relative to their baseline show more shedding than those who lose the same amount gradually.
• Lower protein intake: Semaglutide's appetite suppression can make hitting daily protein targets hard. Inadequate protein deprives follicles of keratin building blocks.
• Female sex: The Gupta et al. 2026 systematic review found females were disproportionately affected. This is consistent with the higher baseline prevalence of telogen effluvium and nutrition-related hair thinning in women.
• Pre-existing low ferritin or iron deficiency: Low serum ferritin is an independent telogen effluvium risk factor even without rapid weight loss. Starting semaglutide with low ferritin compounds the stress.
• Rapid titration without nutritional adaptation: Advancing to a new dose every 4 weeks when intake has not stabilized at the prior dose extends the period of acute appetite suppression and amplifies stress.

Does the Dose Matter? Dose-Stratified Risk Table

Yes. Hair loss risk on semaglutide tracks the weight loss rate, which tracks the maintenance dose. The table below summarizes the relative risk picture by dose tier. This is a synthesis of the pharmacovigilance signal pattern from Gupta et al. 2026 and the STEP 1 weight-loss curve, not a per-dose incidence quote.

Practical implication: staying longer at 1.0 mg or 1.7 mg before advancing to 2.4 mg may reduce the severity of peak appetite suppression and give the body time to nutritionally adapt. No trial has tested this specifically for hair outcomes, but the mechanism is plausible and the downside is small. The microdosing semaglutide guide covers the pharmacokinetic rationale in more depth.

How to Prevent or Reduce Hair Loss on Ozempic or Wegovy

No single intervention eliminates telogen effluvium, but addressing the nutritional root drivers reliably reduces severity. Talk to your prescriber before adding any new supplement.

Protein Target

Hair shafts are about 95 percent keratin. When protein intake falls too low, the body cuts allocation to "non-essential" structures like hair first. A commonly cited target is 0.8 to 1.2 grams of protein per kilogram of body weight per day, adjusted by your provider for activity level and health status. On semaglutide, appetite suppression makes hitting that target effortful, but it is the single most impactful thing you can do for your follicles during weight loss. For broader nutritional context, see the semaglutide dosing guide.

Key Micronutrients to Monitor

Four micronutrients have meaningful evidence ties to telogen effluvium risk:

• Iron and ferritin: Low serum ferritin is the strongest independent risk factor for telogen effluvium. A ferritin level under 30 to 50 ng/mL is commonly cited as a threshold where hair cycling is impaired. Ask your provider to check ferritin specifically, not just hemoglobin.
• Zinc: Supports hair matrix cell proliferation. Deficiency is associated with hair thinning and can be checked in a standard micronutrient panel.
• Vitamin D: Vitamin D receptors are present in hair follicles and have been associated with follicle cycling. Deficiency is common, especially in people with obesity.
• Biotin: Widely marketed for hair growth, but the evidence supports benefit mainly in confirmed deficiency. Taking biotin without deficiency is unlikely to prevent telogen effluvium, though it is generally low risk.

Avoid Extreme Caloric Restriction

Semaglutide's appetite suppression peaks 24 to 72 hours after injection. Some users inadvertently eat far below safe minimums in that window because they simply do not feel hungry. Sustained intake under 1,000 to 1,200 kcal per day amplifies follicle stress well beyond what the weight loss alone would cause. Practical rule: even when you feel no hunger, hit a protein-rich meal in the first 24 hours after each injection.

Could Slower Titration Help?

Some clinicians use a slower titration, staying at each dose step for 6 to 8 weeks instead of the standard 4. No randomized trial has tested this for hair outcomes, but mechanistically it reduces the severity of peak caloric restriction at each step; the downside is slower time-to-target weight loss. See the semaglutide dosage chart for the standard schedule, then ask your prescriber whether a slower variant fits your situation.

Will Hair Grow Back After Semaglutide Hair Loss?

For most people, yes. Telogen effluvium is a temporary disruption to the hair cycle, not permanent follicle destruction. Once the stressor subsides or is managed, follicles return to anagen and begin producing new hair.

Recovery Timeline

Shedding typically peaks during months 2 to 5 of weight loss and slows as weight stabilizes. Most cases resolve 6 to 9 months after weight stabilizes and nutritional status improves. Full density recovery may take the full 9 months, since anagen hair grows at roughly 1 cm per month. A useful early signal: if daily shedding was heavy at months 3 to 5 and noticeably lighter by months 7 to 8, that is reliable progress even before density has visibly returned.

Warning flags that warrant a dermatology consult: shedding that is patchy rather than diffuse, persistence beyond 9 to 12 months after weight stabilizes, or accompanying symptoms like fatigue, cold intolerance, or brittle nails (which can flag thyroid involvement). These patterns may point to androgenetic alopecia, thyroid dysfunction, or another cause that the semaglutide-related shedding may have unmasked rather than caused.

Do You Need to Stop Semaglutide?

Most prescribers do not recommend stopping semaglutide for hair shedding alone. The metabolic benefits are substantial, and the hair loss is driven by the weight loss itself, not the molecule. Stopping also does not immediately end shedding: the telogen effluvium cycle that was already triggered continues through its roughly 3-month telogen phase regardless. This is a clinical conversation with your prescriber, not a home decision. For the broader risk-benefit picture, see the complete semaglutide side effects guide.

What "Low Frequency" Means in FDA Labeling

The Wegovy label entry for alopecia is worth unpacking, because the phrase "listed at low frequency" gets misread in both directions. By FDA convention, adverse-reactions tables in a prescribing information typically report events that occurred above a numeric threshold (commonly 2 percent or 5 percent) and at a rate meaningfully above placebo during the registration trials. Anything that meets the threshold gets listed; anything below it does not, even if it was observed.

"Low frequency" means the event cleared the disclosure threshold but sat in the lower band of the table, not that it is rare in clinical practice. Post-marketing incidence can run higher than the trial figure once a larger, more heterogeneous population is exposed. And an adverse event absent from a label (as with Ozempic and Rybelsus alopecia) does not mean the event does not occur; it means the trial-period rate did not clear the threshold for that indication and dose range.